Uno studio su JNJ-80948543, un anticorpo di reindirizzamento delle cellule T, nel linfoma non Hodgkin (NHL) e nella leucemia linfocitica cronica (LLC)
Uno studio di fase 1, primo sull'uomo di JNJ-80948543, un anticorpo di reindirizzamento delle cellule T, in partecipanti con NHL e CLL
The purpose of this study is to characterize safety and to determine the putative recommended Phase 2 dose(s) (RP2D[s]), optimal dosing schedule(s) and route(s) of administration of JNJ-80948543 in Part A (Dose Escalation) and to further characterize the safety of JNJ-80948543 at the putative RP2D(s) in Part B (Cohort Expansion).
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
-
Macquarie University, Australia, 2109
- Macquarie University Hospital
-
Melbourne, Australia, 3004
- The Alfred Hospital
-
Nedlands, Australia, 6009
- Linear Clinical Research Ltd
-
Randwick, Australia, 2031
- Scientia Clinical Research
-
-
-
-
-
Chongqing, Cina, 400044
- Chongqing University Cancer Hospital
-
Guangzhou, Cina, 510060
- Sun Yat Sen University Cancer Center
-
Tianjin, Cina, 300060
- Tianjin cancer hospital
-
Wuhan, Cina, 430030
- Union Hospital Tongji Medical College of Huazhong University of Science and Technology
-
-
-
-
-
Copenhagen, Danimarca, 2100
- Rigshospitalet
-
Odense, Danimarca, 5000
- Odense University Hospital
-
-
-
-
-
Lille, Francia, 59037
- CHRU de Lille Hopital Claude Huriez
-
Paris, Francia, 75005
- Institut Curie
-
Strasbourg, Francia, 67033
- Institut de Cancerologie Strasbourg Europe ICANS
-
Toulouse, Francia, 31059
- Institut Universitaire du cancer de Toulouse-Oncopole
-
-
-
-
-
Kashiwa, Giappone, 277 8577
- National Cancer Center Hospital East
-
Nagoya, Giappone, 464 8681
- Aichi Cancer Center
-
Tokyo, Giappone, 135 8550
- The Cancer Institute Hospital of JFCR
-
-
-
-
-
Haifa, Israele, 34362
- Carmel Medical Center
-
Jerusalem, Israele, 9112001
- Hadassah Medical Center
-
Tel Aviv, Israele, 64239
- Tel Aviv Sourasky Medical Center
-
-
-
-
-
Gdansk, Polonia, 80 214
- Uniwersyteckie Centrum Kliniczne Osrodek Badan Klinicznych Wczesnych Faz
-
Skorzewo, Polonia, 60-185
- Aidport Sp z o o
-
-
-
-
California
-
Duarte, California, Stati Uniti, 91010
- City of Hope
-
-
New York
-
New York, New York, Stati Uniti, 10065
- Memorial Sloan Kettering Cancer Center
-
New York, New York, Stati Uniti, 10029
- Icahn School of Medicine at Mount Sinai
-
-
Tennessee
-
Nashville, Tennessee, Stati Uniti, 37203
- Sarah Cannon Research Institute
-
-
Texas
-
Houston, Texas, Stati Uniti, 77030
- The University of Texas MD Anderson Cancer Center
-
San Antonio, Texas, Stati Uniti, 78229
- Texas Transplant Institute
-
-
Washington
-
Seattle, Washington, Stati Uniti, 98109
- Seattle Cancer Care Alliance
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Histologic documentation of disease: B-cell non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL) requiring therapy.
All participants must have relapsed or refractory disease with no other approved therapies available that would be more appropriate in the investigator's judgment.
B-cell NHL as defined per the 2016 world health organization (WHO) classification. In addition, the following disease-specific criteria outlined below must be met:
If diffuse large B-cell lymphoma (DLBCL) or other high-Grade B-cell lymphoma: Received, or not eligible for high-dose chemotherapy and autologous stem cell transplantation with curative intent or deemed not eligible or fit for an alternative 2nd line therapy. Participants may be eligible if relapsing after chimeric antigen receptors (CAR-T) cell treatment or while waiting for a CAR-T cell treatment.
If transformed lymphoma from low Grade B-cell malignancies: Received or not a candidate for an approved first-line regimen for DLBCL and received or not eligible for high-dose chemotherapy and autologous stem cell transplantation with curative intent.
If follicular lymphoma (FL) (all grades): Previously treated with a minimum of 2 prior lines of systemic therapy, with at least one prior line containing an anti-CD20 antibody.
If mantle cell lymphoma (MCL), marginal zone lymphoma (MZL) (including nodal, extranodal/MALT, and splenic MZL subtypes): Previously treated with at least 2 lines of systemic therapy. H.pylori-positive gastric MALT lymphoma must have failed prior H. pylori eradication therapy as one of their prior lines .
Waldenstrom macroglobulinemia (WM): Previously treated with at least 1 line of systemic therapy.
small lymphocytic lymphoma/chronic lymphocytic leukemia (CLL/SLL): Relapsed or refractory with at least 2 prior lines of therapy, including a Bruton tyrosine kinase inhibitor (BTK) inhibitor or a BCL2 inhibitor, if eligible. In addition for part B Participants must have measurable disease as defined by the appropriate disease response criteria
- Eastern Cooperative Oncology Group (ECOG) performance status Grade of 0 or 1
- Cardiac parameters within the following range: corrected QT interval (QTc intervals corrected using Fridericia's formula [QTcF]) less than or equal to (<=) 480 milliseconds based on the average of triplicate assessments performed no more than 5 (plus minus [+-] 3) minutes apart
- A female participant of childbearing potential must have a negative highly sensitive serum pregnancy test (beta- human chorionic gonadotropin) at screening and must agree to further serum or urine pregnancy tests prior to the first dose, during the study and until 3 months after the last dose of study treatment
- A female participant must agree not to be pregnant, breastfeeding, or planning to become pregnant while enrolled in this study or within 3 months after the last dose of study treatment
Exclusion Criteria:
- Known active central nervous system (CNS) involvement; Lymphoma with CNS involvement may be allowed in pharmacokinetic/ pharmacodynamic (PK/PD) and expansion cohorts if approved by the study evaluation team (SET)
- Prior solid-organ transplantation
- Autoimmune or inflammatory disease requiring systemic steroids or other immunosuppressive agents (example, methotrexate or tacrolimus) within 1 year prior to first dose of study drug
- Toxicity from prior anticancer therapy has not resolved to baseline levels or to Grade <= 1 (except alopecia, vitiligo, peripheral neuropathy, or endocrinopathies that are stable on hormone replacement, which may be Grade 2)
- Clinically significant pulmonary compromise, particularly the need for supplemental oxygen use to maintain adequate oxygenation
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione sequenziale
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Part A: Dose Escalation
Participants will receive JNJ-80948543 either by subcutaneous (SC) or intravenous (IV) administration to determine the putative recommended Phase 2 dose (RP2D) dosing schedule(s) and route(s) of administration based on safety, pharmacokinetic, pharmacodynamic, and preliminary assessment of efficacy across several dose regimens. |
JNJ-80948543 will be administered as SC or IV injection. |
|
Sperimentale: Part B: Cohort Expansion
Participants will receive JNJ-80948543 by SC or IV administration. |
JNJ-80948543 will be administered as SC or IV injection. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Number of Participants with Dose-limiting Toxicity (DLT)
Lasso di tempo: Up to 4 Years 3 months
|
Number of participants with DLT will be reported. The DLTs are specific adverse events and are defined as any of the following: high grade non-hematologic toxicity, or hematologic toxicity. |
Up to 4 Years 3 months
|
|
Number of Participants with Adverse Events (AEs)
Lasso di tempo: Up to 4 Years 3 months
|
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. |
Up to 4 Years 3 months
|
|
Number of Participants with AE by Severity
Lasso di tempo: Up to 4 Years 3 months
|
Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE). Severity scale ranges from Grade 1 (Mild) to Grade 4 (Life-threatening). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event. Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) will be graded as per American Society for Transplantation and Cellular Therapy (ASTCT). |
Up to 4 Years 3 months
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Serum Concentration of JNJ-80948543
Lasso di tempo: Up to 4 Years 3 months
|
Serum samples will be analyzed to determine concentrations of JNJ-80948543 using a validated, specific, and sensitive method. |
Up to 4 Years 3 months
|
|
Number of Participants with Presence of Anti-Drug Antibodies of JNJ-80948543
Lasso di tempo: Up to 4 Years 3 months
|
Number of participants with presence of anti-drug antibodies of JNJ-80948543 will be assessed. |
Up to 4 Years 3 months
|
|
Overall Response Rate (ORR)
Lasso di tempo: Up to 4 Years 3 months
|
ORR is defined as the percentage of participants who have a best response of partial response (PR) or better. |
Up to 4 Years 3 months
|
|
Complete Response (CR) Rate
Lasso di tempo: Up to 4 Years 3 months
|
CR rate is defined as the percentage of participants who achieve a best response of CR. |
Up to 4 Years 3 months
|
|
Rate of VGPR or Better for Participants with Waldenstrom Macroglobulinemia (WM)
Lasso di tempo: Up to 4 Years 3 months
|
The response criteria planned to be used for participants with WM includes a category of VGPR, which is clinically understood to be better than PR but not as good as CR. For participants with WM, this rate is defined as the proportion of participants who achieve a best response of VGPR or better. |
Up to 4 Years 3 months
|
|
Time to Response (TTR)
Lasso di tempo: Up to 4 Years 3 months
|
TTR is defined for participants who achieved PR or CR as the time from the first dose of study drug to first response of PR or CR. |
Up to 4 Years 3 months
|
|
Duration of Response (DOR)
Lasso di tempo: Up to 4 Years 3 months
|
DOR is defined for participants who achieved a response of PR or better as the time between the date of initial documentation of first response of PR or better to the date of first documented evidence of progressive disease or death. |
Up to 4 Years 3 months
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Direttore dello studio: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Processi patologici
- Neoplasie
- Malattia cronica
- Attributi della malattia
- Malattie del sistema immunitario
- Neoplasie per tipo istologico
- Malattie ematologiche
- Malattie linfatiche
- Malattie linfoproliferative
- Disturbi immunoproliferativi
- Leucemia, cellule B
- Linfoma
- Leucemia, linfoide
- Leucemia
- Condizioni patologiche, segni e sintomi
- Malattie emiche e linfatiche
- Leucemia, linfocitica, cronica, cellule B
- Linfoma non Hodgkin
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- CR109174
- 2022-000685-18 (Numero EudraCT)
- 80948543LYM1001 (Altro identificatore: Janssen Research & Development, LLC)
- 2023-504187-42-00 (Identificatore di registro: EUCT number)
- 2023 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .